About Theraclone
Headquartered in Seattle, Theraclone Sciences is a discovery-stage biotech developing novel therapeutic antibodies for the treatment of infectious disease and inflammation. Our proprietary discovery platform allows us to comprehensively screen and identify the rare antibodies that select individuals produce to successfully ward off disease.
Central to our discovery approach, we identify antibodies produced naturally by human memory B cells in response to disease-causing agents. This allows us to identify monoclonal antibodies that are likely to be highly effective in combating disease in a broad patient population. The antibodies identified through our discovery process can be further studied as tools for vaccine development.
Our most advanced development programs are focused on infectious disease including novel antibodies to fight pandemic and seasonal influenza. Our flu program is in partnership with Zenyaku Kogyo Co., Ltd. We have also recently partnered with the International AIDS Vaccine Initiative to identify two of the most potent and broadly neutralizing anti-HIV antibodies yet discovered, despite more than 10 years of intensive research by investigators worldwide.
Theraclone is a venture-funded company founded in 2005. Our investors include ARCH Venture Partners, Canaan Partners, Healthcare Ventures, Amgen Ventures, MPM, and AREE. We are actively seeking development partners in the U.S., Europe, and Japan to help us create and commercialize antibody therapeutic products.